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For more than 15 years, the tautomerase active site
of macrophage migration inhibitory factor (MIF) and
its catalytic residue Pro1 have been being targeted
for the development of therapeutics that block acti-
vation of its cell surface receptor, CD74. Neither the
biological role of the MIF catalytic site nor the mech-
anistic details of CD74 activation are well under-
stood. The inherently unstable structure of CD74
remains the biggest obstacle in structural studies
with MIF for understanding the basis of CD74 activa-
tion. Using a novel approach, we elucidate the mech-
anistic details that control activation of CD74 by MIF
surface residues and identify structural parameters
of inhibitors that reduce CD74 biological activation.
We also find that N-terminal mutants located deep
in the catalytic site affect surface residues immedi-
ately outside the catalytic site, which are responsible
for reduction of CD74 activation.
INTRODUCTION
Macrophage migration inhibitory factor (MIF) is an inflammatory
protein with an eponymous activity that was first described using
conditioned media of activated lymphocytes almost 50 years
ago (Bloom and Bennett, 1966; David, 1966). As a cytokine,
MIF has some unique properties. It is constitutively expressed
with no signal sequence, is present in the cytosol of all nucleated
cells where it interacts with p53 and other proteins, has an enzy-
matic site, possesses a solvent channel along the 3-fold axis of
the trimer, and is exported to the extracellular milieu in response
to diverse stimuli or cell stress (Conroy et al., 2010). MIF binds
the type II receptor CD74 (Leng et al., 2003) and the chemokine
receptors CXCR2 and CXCR4 (Bernhagen et al., 2007; Liehn
et al., 2013), mediating distinct signaling mechanisms that lead
to a variety of biological responses (Bernhagen et al., 2007;Chemistry & Biology 22, 1197–120Leng et al., 2003). These activities include regulation of chemo-
taxis, proliferation, angiogenesis, and atherogenesis, with ef-
fects on sepsis and general inflammation, autoimmune disease,
and cardiovascular disease, as well as cancer growth, survival,
and metastases (Ayoub et al., 2008; Bach et al., 2008; Noels
et al., 2009).
CD74 also has an intracellular role as the invariant chain asso-
ciated with the processing of major histocompatibility complex
(MHC) class II proteins, and is destined for proteolysis to pro-
duce a 15mer peptide (known as CLIP) that binds to the MHC
class II antigen site before it is displaced by antigenic peptides
(Riberdy et al., 1992). About 5% of the expressed CD74 traffics
to the cell surface independent of MHC class II and functions
as theMIF receptor. The recombinant CD74 extracellular domain
is inherently unstable due to a number of flexible regions (Jasan-
off et al., 1995, 1998), its propensity to be cleaved by enzymes
(Bergmann et al., 2013; Riberdy et al., 1992), and the absence
of the transmembrane region that contributes to the stability of
the CD74 trimer (Ashman and Miller, 1999). Consequently, only
the nuclear magnetic resonance structure of the small trimeric
domain of extracellular CD74 is known (Jasanoff et al., 1998).
Attempts to use the extracellular CD74 domain for structural
studies with MIF have not been successful to date.
The three-dimensional structure of human MIF (Sun et al.,
1996) has the same topology as two microbial enzymes that
are members of the tautomerase superfamily, 4-oxalocrotonate
tautomerase and 2-carboxymethyl-5-hydroxymucanate isom-
erase (Subramanya et al., 1996). Other than the general base
catalyst, Pro1, found deep within a catalytic cavity, the proteins
that belong to the tautomerase superfamily do not have signifi-
cant sequence similarity. The members of this superfamily
form dimers (Almrud et al., 2002), trimers (Sun et al., 1996), or
hexamers (Subramanya et al., 1996) with catalytic sites at clefts
between subunits, resulting in two, three, and six sites for each
oligomer. All of these proteins, including MIF, have a pKa <7.0
for Pro1 (Stivers et al., 1996; Swope et al., 1998) that is three
pH units lower than a typical N-terminal proline, consistent
with a role as a catalytic base. A physiological substrate for
MIF has not been identified, but natural (p-hydroxyphenylpyru-
vate) and unnatural ligands (D-dopachrome and its analogues)5, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1197
were fortuitously found as ‘‘model’’ tautomerase substrates
(Rosengren et al., 1996, 1997) and used for structure-based in-
hibitor design (Lubetsky et al., 1999, 2002) or high-throughput
screening (Cho et al., 2011; Ouertatani-Sakouhi et al., 2010).
Interestingly, the MIF-ligand complexes can function as (1) dis-
ruptors of MIF-CD74 interactions (no binding) (Cournia et al.,
2009; Takahashi et al., 2009), (2) wild-type MIF (no effect on
MIF binding to CD74) (Cournia et al., 2009), (3) up-regulators of
CD74 binding and signaling (Jorgensen et al., 2010), or (4)
CD74 antagonists (Cho et al., 2011; Jorgensen et al., 2011).
The structural source of these different functional effects by li-
gands binding to the same site is not understood, and the pa-
rameters distinguishing these various effects remain unknown.
Using MIF N-terminal mutants and MIF-covalent inhibitors, we
investigated the biological role of the MIF catalytic pocket and
identified mutant and ligand properties that provide new insight
into the functional activation of CD74. We elucidated the surface
residues that play a key role in activation of CD74, and provide
the first detailed analysis of the structural features of catalytic in-
hibitors that dysregulate CD74 activation.
RESULTS
The MIF Active Site in Activation of CD74
We probed residues of the MIF enzymatic pocket involved in re-
ceptor activation by characterization of MIF mutants and MIF-
covalent inhibitor complexes using a previously established
lung neutrophil recruitment assay (Takahashi et al., 2009).
CD74 is not expressed by neutrophils. However, intratracheal
or intranasal administration of recombinant MIF activates CD74
on the surface of alveolar macrophages, leading to p44/p42
MAPK signaling and the secretion of two neutrophil-recruiting
chemokines, MIP-2 and KC. There is no evidence that MIF inter-
acts with any chemokine receptor on neutrophils, as neutrophil
recruitment to the lung is inhibited by an anti-CD74 monoclonal
antibody (Figure S1).
An alanine insertion mutant between Pro1 andMet2 of the MIF
sequence (abbreviated as the PAM mutant) had already been
structurally characterized, moving the catalytic residue Pro1
into the center of the MIF active site pocket (Lubetsky et al.,
1999). In the present study two additional alanine insertions,
PAAM (PA2M) and PAAAM (PA3M), were engineered and used
with PAM to probe functional MIF-CD74 interactions. The ratio-
nale behind this approach was that the position of Pro1 was
known to be at the center of the active site pocket (PAM) (Lubet-
sky et al., 1999), while for PA2M and PA3MPro1 was predicted to
be close to the protein-solvent interface and in the solvent,
respectively. The expectation was there would be (1) no biolog-
ical activity for all three mutants if a side chain from CD74 occu-
pied the aromatic active site and was responsible for most of the
binding energy, similar to a tryptophan residues for growth hor-
mone interacting with its receptor (Clackson andWells, 1995), (2)
full biological activity for PAM, but no activity for PA2M and PA3M
if the binding interactions involved surface residues at the active
site-solvent boundary, or (3) full activity for all three mutants if
neither the catalytic site nor the surrounding surface area were
involved in CD74 interactions. The in vivo results indicate that
the PAM mutant has neutrophil recruitment activity similar to
that of wild-type MIF, and the PA2M and PA3M mutants have1198 Chemistry & Biology 22, 1197–1205, September 17, 2015 ª201no significant activity when compared with control (Figure 1A).
We also determined whether the reduction of activity was due
to the inability of the PA2M and PA3M mutants to bind CD74 or
whether these mutants functioned as antagonists, by adminis-
tering wild-type MIF with different stoichiometries of PA2M or
PA3M (Figure 1B). The results showed a dose-dependent antag-
onist effect for PA2M at stoichiometries of 1:1 and 1:5 (wild-type
MIF/PA2M). The PA3M mutant at the same stoichiometries also
showed an antagonist effect but did not achieve significance be-
tween the twoMIF/PA3M stoichiometries. High-resolution struc-
tures of the PA2M and PA3M mutants were determined (Table
S1) to confirm the location of Pro1 (Figures 1C–1E). Based on
these structures and that of wild-type MIF (PDB: 3DJH), the pro-
tein-solvent interface is in the proximity of the terminal side chain
atoms for residues Lys32 and Tyr36 at the entrance of the active
site pocket (Figure 1E). The mutants distinguished whether
occupation of part of the catalytic site (PAM), the entire site
(PA2M), or extension into the solvent (PA3M) results in differ-
ences for lung neutrophil recruitment due to CD74 binding and
signaling.
We determined the structures of four covalent inhibitors com-
plexed to MIF (Table S2). The electron density map of each
inhibitor (1, 10, 14, and 21) covalently bound to Pro1 and their
second-order kinetics are provided in Figures 2 and 3, and the
mechanism of covalent formation is shown in Figure S2. The
size and orientation of each covalent inhibitor bound to Pro1 is
unique, providing an alternative approach relative to the PAnM
(n = 1–3) mutants to study lung neutrophil recruitment (Figures
4A–4C). We measured the recruitment of neutrophils to the
lung by intranasal instillation of each MIF-inhibitor complex at a
dose of 1 mg (Figure 4D). Two of the MIF-inhibitor complexes
(MIF-1 and MIF-10) have reduced neutrophil recruitment activity
(%50%) and possess chemical moieties in the solvent or at the
protein-solvent interface (Figure 4B). Covalent modification by
14 results in a small chemical adduct buried deep inside the
active site (Figure 4C). The neutrophil recruitment activity of
the MIF-14 complex is similar to that of apo MIF (Figure 4D). In-
hibitor 21 occupies the active site facing the channel along the
3-fold axis away from the solvent (Figure 4C) and, like 14, has
activity similar to that of wild-type MIF. The MIF-1 and MIF-10
complexes were further characterized and found to have a
dose-dependent antagonist effect (Figure 4E).
Based on the crystallographic and in vivo results, the PAnM
mutants and the covalent complexes were segregated into
two groups. The first group is composed of the mutants or
MIF-covalent inhibitor complexes that extend to either the
MIF-solvent interface or into the solvent. These are the
PA2M and PA3M mutants and the MIF-1 and MIF-10 com-
plexes, which cause reduction of neutrophil recruitment to
the lung. The second group (PAM mutant, MIF-14, and MIF-
21) has the proline residue or inhibitors buried in the active
site pocket, resulting in neutrophil-recruiting activity similar
to that of wild-type MIF. These results indicate that occupancy
of the catalytic site without perturbing the solvent interface
does not inhibit activation of CD74 and neutrophil-recruiting
activity. Any molecule that reaches the protein-solvent inter-
face (PA2M and MIF-10) or extends out of the active site
(PA3M and MIF-1) reduces MIF-mediated neutrophil-recruiting
activity to lung.5 Elsevier Ltd All rights reserved
Figure 1. In Vivo Functional Assays of PAnM
Mutants and Comparison between the Posi-
tion of Pro1 in the Crystal Structures of
PAnM Mutants and Wild-Type MIF
(A) In vivo neutrophil recruitment assay demon-
strates that statistically significantly fewer neutro-
phils are recruited to the lung by PA2M and PA3M,
while PAM has activity similar to that of wild-type
MIF.
(B) In vivo assay of wild-type MIF with the PA2M or
PA3M mutant at 1:1 and 1:5 stoichiometric ratios
shows antagonism by these two mutants.
(C) The 2Fo-Fc electron density maps of PA2M and
PA3M. The maps were contoured at 1.5s and 1s,
respectively.
(D) Comparison of the proline positions for wild-
type, PAM, PA2M, and PA3M after superposition of
residues 2–114 for wild-type MIF and the equiva-
lent residues from the mutants. The gray shape
represents the active-site pocket of wild-type MIF
as determined by the solvent surface. The green,
cyan, magenta, and yellow carbon atoms for Pro1
represent wild-typeMIF, andmutants PAM, PA2M,
or PA3M, respectively.
(E) The MIF-solvent interface at the surface of
the active site is defined by the terminal side-
chain atoms of the active-site residues Lys32
and Tyr36. The Pro1 position of PAM, PA2M,
and PA3M is shown in a different orientation
relative to (D).Role of Pro1 and N-terminal Region in Activation
of CD74
Previous studies that reported on Pro1 mutants suggested that
this residue is important for MIF biological activity (Fingerle-
Rowson et al., 2009; Swope et al., 1998). One of these studies
showed that a Pro1 to glycine mutation (P1G) resulted in a cata-
lytically inactive protein that maintains significant, albeit
reduced, binding to its cell surface receptor CD74, and reduced
biological activity (Fingerle-Rowson et al., 2009). This is in
contrast to the results of the PAnM insertion mutants and the co-
valent inhibitors described above. We decided to probe the role
of Pro1 in more detail in order to better understand the published
findings. In addition to studying Pro1, we also sought answers
with respect to the multiple conformations that Met2 adopts in
various MIF crystal structures and whether these are related to
protein function. We deleted the initiating methionine and Pro1
(DP1, resulting in the MIF sequence Met2-Ala114), mutated
Pro1 to methionine (P1M with the mutant Met1 followed by the
wild-type sequence Met2-Ala114), and created the single-site
mutation Met2 to alanine (M2A). The P1M mutant had neutro-
phil-recruiting activity similar to that of wild-type MIF, indicating
that Pro1 is not needed for activation of CD74 (Figure 5A). M2A
and the deletion mutant DP1 reduced neutrophil recruitment ac-
tivity by 50% (Figure 5A). The three-dimensional structures
were as expected for P1M and M2A (Table S3, Figure 5B). Sur-
prisingly, one of two conformations for Met2 in the DP1 deletion
mutant overlaps with the location of the wild-type Pro1, but thisChemistry & Biology 22, 1197–120cannot be attributed to any functional activity because the M2A
mutant that contains Pro1 in the wild-type location also has 50%
neutrophil-recruiting activity of wild-type MIF (Figure 5B). Com-
parison of B factors from wild-type MIF (PDB: 3DJH) and P1G
MIF (PDB: 1P1G), along with DP1, P1M, and M2A mutants in
this study, provided some insight into their activities (Figure 5C).
The last three mutants (DP1, M2A, and P1G) had increased B
factors at the N-terminus, in contrast to the P1M mutant.
Changes in the N-terminal B factors were accompanied with
B-factor changes at surface-exposed residues outside the cata-
lytic cavity. For example, all four N-terminal mutants have an
increased B factor for K32, but mutation of this residue did not
affect CD74 activation (Figure 5C). However, residues Tyr36
and Lys66 have a common B factor increase only for P1G,
DP1, and M2A compared with P1M or wild-type MIF. B-Factor
analysis has been used to infer the dynamics of residues or re-
gions of proteins (Lu et al., 2006). Although the B-factor values
can only be correlated qualitatively with in vivo activities, they
provide insight into the structural and dynamic features of sol-
vent-exposed residues at the cavity that lead to different neutro-
phil-recruiting activities. This conclusion is also supported by the
findings from the previous section, which showed that chemical
moieties of inhibitors or alanine insertion mutants that reach or
penetrate the protein-solvent interface (PA2M, PA3M, MIF-1,
and MIF-10) bind but do not effectively activate CD74. We
mutated a number of solvent-exposed residues and tested
in vivo function to glean support for this conclusion.5, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1199
Figure 2. Chemical Structure of Com-
pounds 1, 10, 14, and 21 and the Electron
Density of Each Pro1-Covalent Product
Illustration of the chemical structures of com-
pounds 1, 10, 14, and 21. The 2Fo-Fc maps of the
compounds complexed to Pro1, contoured at
1.5s, are also shown. Pro1 is shown in yellowwhile
compounds 1, 10, 14, and 21 are in orange, pur-
ple, dark green, and gold, respectively.MIF Surface Residues Involved in Key Interaction Points
with CD74
Following the observations of the previous section, residues
K32, Y36, and K66 were tested as single alanine mutants. We
made a number of double mutants and tested them in vivo to
identify other MIF surface residues that might interact with
CD74. All the double mutants chosen for this study are located
around the cavity (P34A/Q35A, S63A/I64A, and W108A/N109A)
except for a control mutant (Q24A/Q25A), which is located on
the surface of the first a helix away from the cavity. For the dou-
ble mutants that were inactive or partially active, we made single
alanine mutants to determine their activities (Figure 6A). Interest-
ingly the alanine mutant of K32, the residue with a dramatic B-
factor increase for the fully functional P1M mutant, does not
affect the biological activity. P34A/Q35A and the control mutant
Q24A/Q25A also maintain full activity. I64A and W108A are
partially active. Y36A, K66A, and N109A do not have any neutro-
phil-recruiting activities. Crystallographic analyses of Y36A,
K66A, N109A, and the control mutant Q24A/Q25A showed that
the mutations caused no conformational changes (Table S4).1200 Chemistry & Biology 22, 1197–1205, September 17, 2015 ª2015 Elsevier Ltd All rights rSurprisingly, I64A and W108A could not
be crystallized under normal MIF crystal-
lization conditions or under new crystalli-
zation screening conditions. Therefore,
we are unable to determine with certainty
whether any unanticipated conforma-
tional changes are responsible for their
partial activity. Nonetheless, the findings
define surface regions around the active
site that are involved in functional interac-
tions with CD74 (Figure 6B).
DISCUSSION
In the absence of anMIF-CD74 co-crystal
structure, we used a novel approach to
identify MIF residues that activate CD74.
Alanine insertion mutants between Pro1
and Met2 as well as MIF-inhibitor
complexes were employed. Neither the
PAnM mutants nor the MIF-covalent in-
hibitor complexes can dissociate during
the time course of the in vivo experiment.
The use of a covalent inhibitor also pre-
vents any off-target effects that can
complicate the interpretation of the re-
sults. This allowed us to make definitive
conclusions about CD74 activation. Ourfindings show that Pro1 and the active site pocket of MIF are
not involved in interactions with CD74. These findings support
the concept that a chemical moiety of an MIF inhibitor outside
the active site is important for reducing MIF activation of
CD74. We analyzed the surface-exposed atoms of proline for
each PAnM mutant and the solvent-exposed atoms for each co-
valent inhibitor. We observed that the active proteins (wild-type
MIF, PAM, MIF-14, and MIF-21) have a solvent-exposed surface
area of atoms (either proline atoms or atoms from the covalent
inhibitors) of 21 A˚2 or less. The partially active or inactive proteins
have solvent-accessible areas of at least 44 A˚2 (Table S5). This is
likely to be one of the physicochemical parameters that leads to
CD74 antagonism.
There are three related studies that include three-dimensional
structures of MIF-ligand complexes with CD74 binding or func-
tional data in which the functional effects of chemical moieties
outside the active site were not examined (Cho et al., 2011; Pan-
touris et al., 2014; Takahashi et al., 2009). In two of these studies,
chemical moieties that penetrate into the solvent significantly
reduce binding to CD74 (Cho et al., 2011; Pantouris et al.,eserved
Figure 3. Kinetic Analyses of MIF-Inhibitor
Complexes
Wild-type MIF was mixed with equal stoichiome-
tries of 1, 10, 14, and 21, and the tautomerase
activity of MIF was assessed over time. The data
were fitted in a hyperbolic curve, and the second-
order rate constants were calculated according to
the equation y = A/(Akt + 1), where A is initial
effective free [MIF] and k is second-order rate
constant. The curves were plotted in ORIGIN and
are shown. The curve for only MIF-1 is shown.2014). In the third study, a prototypical competitive inhibitor of
human MIF, (S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole
acetic acid methyl ester (ISO-1), decreased CD74-dependent
neutrophil recruitment to the lung by 50% (Takahashi et al.,
2009). We analyzed the MIF-ISO-1 structure (PDB: 1LJT) and
found that a chemical moiety from ISO-1 protrudes from the
active site into the solvent (Figure S3) (Lubetsky et al., 2002).
These findings support the concept that chemical moieties of
MIF inhibitors outside the active site are important for regulating
CD74 activation and signaling.
B-Factor analysis of Pro1 or Met2 mutants (P1G, P1M, and
M2A), and the deletion mutant of Pro1 (DP1) showed differencesFigure 4. Orientations of 1, 10, 14, and 21 Chemical Adducts Covalent
(A) The chemical adduct of 1 (orange carbon atoms) and 10 (purple carbon atom
(dark-green carbon atoms) and 21 (gold carbon atoms) remain buried in the acti
(B) The positions of 1 and 10 in the context of the protein-solvent interface.
(C) The positions of 14 and 21 in the context of the protein-solvent interface.
(D) Percentage neutrophils in the bronchoalveolar lavage recruited by MIF-1, MI
(E) The two MIF-inhibitor complexes (MIF-1 and MIF-10) that reduce lung neutro
complexes with wild-type MIF at 1:1 and 1:5 stoichiometric ratios, respectively.
Chemistry & Biology 22, 1197–120with respect to wild-type MIF. The findings suggest that these
mutants influence the dynamics of surface residues surrounding
the cavity to reduce or abolish CD74 activation. Functional ana-
lyses of alanine mutants for residues identified Tyr36, Lys66, and
Asn109 as key residues that control activation of CD74. Other
residues, such as Lys32, Pro34, and Gln35, as well as control
residues for this experiment (Gln24 and Gln25), are not involved
in CD74 activation. A similar B-factor analysis has been used to
directly explain the biological properties of other proteins (Hsieh
et al., 2013; Marx et al., 2008).
The findings in this study reveal that neither abolishing the tau-
tomerase activity nor mutation of Pro1 affects protein-proteinly Bonded to Pro1 and the In Vivo Functional Assay of Each Complex
s) penetrates or is at the protein-solvent interface. Chemical adducts from 14
ve-site pocket.
F-10, MIF-14, and MIF-21.
phil recruitment function as antagonists, based on the activity of mixtures of
5, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1201
Figure 5. Neutrophil Recruitment Assay and Crystallographic B-Factor Analyses of MIF N-Terminal Mutants
(A) In vivo neutrophil recruitment assay of P1M,DP1, andM2A. TheDP1 andM2A inhibit recruitment of neutrophil to the lung by50%. The reduction of P1Mwas
not statistically significant.
(B) The 2Fo-Fc electron density maps of P1M, M2A, and DP1 mutants. The maps were contoured at 1.5s.
(C) Analyses of the residual crystallographic B factors of P1M, P1G, M2A, and DP1. Mutation of P1M increased the normalized B factors in two particular regions
outside the active site. These regions are marked with a star. The P1G, M2A, and DP1 mutants increase the B factors of the highlighted N-terminal part of the b1
strand, resulting in changes that eventually reach the surface.interactions and reduction of CD74 activation. The mutants of
Pro1 (and Met2) influence the B factors of specific surface resi-
dues that reduce CD74 activation when mutated, indicating
that residues at the surface surrounding the catalytic site pocket
of MIF are involved in activation of CD74. The mechanism for the
N-terminal mutants that leads to B-factor changes at specific
surface residues remains to be determined by molecular dy-
namics simulations. The knowledge gained herein advances
our understanding of the structural and chemical basis of
CD74 activation and provides vital information for the develop-
ment of new MIF-based therapeutics.
SIGNIFICANCE
Macrophage MIF is a cytokine that is expressed in all types
of human cells and plays a key role in many diseases via its1202 Chemistry & Biology 22, 1197–1205, September 17, 2015 ª201binding to the cell surface receptor CD74. A small-molecule
inhibitor of CD74 is yet to be discovered, while there are
numerous tautomerase inhibitors of MIF. The MIF-inhibitor
complexes have varying effects in their interactions with
CD74 including abolishing interactions, up-regulating
CD74 signaling, and antagonizing CD74 signaling, or have
no effect on CD74 function. Our study provides the first
comprehensive analysis of the MIF parameters that control
functional activation of CD74, and clarifies the properties
of MIF inhibitors that effectively inhibit CD74. First, the cata-
lytic pocket of MIF is not involved in interactions with CD74.
However, inhibitors that bind to the pocket must penetrate
the protein-solvent interface to function as CD74 antago-
nists. Second, mutations of N-terminal residues affect key
surface residues that cause reduction or complete inhibition
of CD74 activation when mutated. These key residues are5 Elsevier Ltd All rights reserved
Figure 6. Surface Mutations Reveal the MIF
Residues that Play a Key Role in Activation
of CD74
(A) Neutrophil recruitment activities of the surface
mutants. The effect of Y36A, K66A, and N109 are
not statistically significant compared with saline
alone (p > 0.05). The partial agonists I64A and
W108A are statistically significant compared with
MIF (p < 0.01) and saline (p < 0.05).
(B) The MIF surface mutants used in this study are
shown in different colors according to their in vivo
activities and crystallographic structures. The red
highlighted regions show the surface residues that
do not activate CD74 with a three-dimensional
structure illustrating that there are no conforma-
tional changes. Orange denotes the two partial
agonists that could not be crystallized. The fully
active surface residues are shown in blue.mapped on the three-dimensional surface of MIF to identify
the region involved in CD74 interactions. Mutants of resi-
dues that do not affect CD74 activation are also used to pro-
vide a more comprehensive map for understanding these
interactions. This study enhances our understanding of
MIF-mediated CD74 activation and aids in the development
of novel therapeutics.
EXPERIMENTAL PROCEDURES
Mutagenesis
The MIF mutants were synthesized using the megaprimer method (Ke and
Madison, 1997). The pET-11b/WT MIF served as the template, and the oligo-
nucleotides shown in the Supplemental Information were amplified, producing
the desired mutation. The clone of PAM was previously reported (Lubetsky
et al., 1999).
Expression and Purification of Recombinant Human MIF and MIF
Mutants
Expression and purification of recombinant human MIF and MIF mutants were
performed as described previously (Lubetsky et al., 1999). Each pET-11b
plasmid containing the cDNA of interest was transformed in Escherichia coli
BL21-Gold (DE3) cells. The cells were grown at 37C to an OD600 of 0.6 and
induced using isopropyl b-D-1-thiogalactopyranoside at final concentration
of 1 mM. After 4 hr at 37C, the cells were harvested and stored at20C until
further use. For purification, the cells were thawed and lysed using sonication
in 20 mM Tris (pH 7.4) and 20mMNaCl containing a protease inhibitor cocktail
tablet. Cell debris was removed via centrifugation for 45min at 28,0003 g. The
supernatant was filtered using a syringe-driven filter unit and loaded onto a
Q-Sepharose column (120 ml) connected in series with an SP column
(55 ml). Both wild-type MIF andMIF mutants were not retained from either col-
umns and were collected as flow-though, which was 95% pure. MIF was
further purified using size-exclusion chromatography (16/60 Superdex 75) in
the same buffer.
Enzyme Kinetics
Kinetic analyses of MIF-covalent inhibitor formation were performed using the
Tecan Infinite M200 spectrophotometer at 306 nm with a Corning semitrans-
parent 96-well plate. Prior to carrying out any experiment, a stock solution of
4-hydroxyphenylpyruvate (4-HPP) in 0.5 M ammonium acetate (pH 6.2) was
prepared and equilibrated for 24 hr at room temperature to allow for keto-
enol equilibration. MIF and each inhibitor were mixed, and an aliquot was
removed at various time points and added to wells containing the tautomerase
mixture to measure the remaining tautomerase activity. Each measurement
lasted 90 s with readings taken every 10 s. The volume of the tautomerase re-
actionmixture was 150 ml and contained 0.416Mborate (pH 6.2), 0.5mMHPP,
DMSO or inhibitor dissolved in DMSO, and 5 mM MIF. The final concentrationChemistry & Biology 22, 1197–120of 1, 10, 14, and 21was 5 mM (equal stoichiometric ratios withMIF). In all cases,
controls and compounds were at a final concentration of 1% (v/v) DMSO. All
experiments were performed at 25C. The data were fitted to a hyperbolic
curve using ORIGIN 9.0, and the second-order rate constants were calculated
as described elsewhere (Crichlow et al., 2012).
Murine In Vivo Recruitment of Neutrophils to the Lung
Neutrophil recruitment was measured using C57BL/6J mice (8–12 weeks old)
according to the protocol described by Fan et al. (2013). All samples were
administrated to murine lungs via the intranasal route as 50-ml saline solutions
with recombinant human MIF at 1 mg, and the anti-murine CD74 monoclonal
antibody (BD Pharmingen, cat. #555317) at 10 mg. MIF mutants and each of
the MIF-covalent inhibitor complexes were also administrated as solutions
containing 1 mg of sample. Each compoundwas incubated withMIF at 1:1 stoi-
chiometric ratio at 4C for 24 hr. The complete modification of MIF by each in-
hibitor at 24 hr was based on the second-order kinetics of each inhibitor. For
in vivo antagonist assays, wild-type MIF and each mutant or MIF-inhibitor
complex were administered at 1:1 and 1:5 stoichiometric ratios (wild-type
MIF/MIF mutant or MIF-inhibitor complex). The total number of neutrophils
was calculated using the differential cell count of a minimum number of 200
cells stained with HEMA 3 (Fisher Scientific). For direct comparison of two da-
tasets the two-tailed t test was used. The protocol followed for the mouse
experiments was reviewed and approved by the Yale University Institutional
Animal Care and Use Committee.
Crystallization, Data Collection, Structure Determination,
and Refinement
The MIF mutants and MIF-covalent inhibitor complexes were crystallized by
vapor diffusion in hanging-drop trays. PurifiedMIFmutants were concentrated
to 18 mg/ml. For the MIF-covalent inhibitor complexes, MIF was concentrated
to 18 mg/ml, mixed with each compound at 1:3 M ratio (MIF/inhibitor), and
incubated at 4C overnight. Before crystallization, all samples were spun for
5 min at 16,000 3 g. Equal volumes of mutant or MIF-inhibitor complex were
mixed with the well reservoir (2 ml:2 ml) and allowed to equilibrate at 20C. Crys-
tals appeared within 2 weeks. PA2M and PA3M were crystallized in 20 mM
2-(N-morpholino)ethanesulfonic acid (pH 6.5) and 2 M ammonium sulfate.
The other mutants and the four MIF-inhibitor complexes were crystallized in
20 mM Tris (pH 7.4), 2 M ammonium sulfate, and 3% 2-propanol. All crystals
were flash-frozen in the mother liquor with 25% glycerol. Diffraction data of
PA2M were collected at beamline X25 (wavelength = 1.1 A˚) of the Brookhaven
National Synchrotron Light Source. Diffraction data of PA3M, P1M, Q24A/
Q25A, and theMIF-covalent inhibitor complexes were collected at Yale School
of Medicine on an R-AXIS IV++ image plate detector (Rigaku) with a Rigaku
007 rotating copper anode X-ray generator (wavelength = 1.5418 A˚). Diffrac-
tion data of Y36A, K66A, and N109A were also collected at Yale School of
Medicine on a Rigaku Pilatus 200K Detector using the same type of generator
described above. For M2A and DP1, the diffraction data were collected at
St. Louis University School of Medicine, using an R-AXIS IV++ image plate5, September 17, 2015 ª2015 Elsevier Ltd All rights reserved 1203
detector, wavelength = 1.5418 A˚. All datasets were collected at temperatures
between 90 and 100 K. All datasets (except PA3M) were integrated and scaled
using HKL2000 programs suite (Otwinowski and Minor, 1997). For PA3M, the
dataset was integrated with MOSFLM (Battye et al., 2011) and scaled with
SCALA (Evans, 2006). The structures were solved by molecular replacement
using PHASER (McCoy et al., 2007) and refined by PHENIX (Adams et al.,
2010) (PA2M and PA3M) or REFMAC (Winn et al., 2003) (for the other mutants
and MIF-covalent inhibitor complexes). Ramachandran analysis showed 0%
outliers and 98.20% (P1M), 98.81% (M2A), 98.79% (DP1), 98.88% (PA2M),
97.72% (PA3M), 98.81% (Q24A/Q25A), 98.33% (Y36A), 98.81% (K66A),
97.92% (N109A), 98.51% (MIF-1), 99.09% (MIF-10), 99.11% (MIF-14), and
98.21% (MIF-21) residues in preferred regions. Topology models of the
inhibitors were produced by the PRODRG server (Schuttelkopf and van Aalten,
2004) and fitted in the model using Coot (Emsley et al., 2010). The 2Fo-Fcmaps
were generated by FFT (Winn et al., 2011) and visualized in PyMOL (DeLano,
2002). The structure of wild-type MIF (PDB: 3DJH) was superposed onto
the MIF mutants and MIF-inhibitor complexes using SUPERPOSE (CCP4
supported) (Winn et al., 2011). The root-mean-square deviation values
showed high superposition agreement with wild-type MIF. The values varied
between 0.10 and 0.29 A˚ and are provided in Table S6. Analyses of the
solvent-accessible surface area of atoms in MIF-inhibitor complexes or the
proline in wild-type and PAnM mutants were calculated using AREAIMOL
(Winn et al., 2011). The detailed statistics of the datasets are presented in
Table S1 (PA2M and PA3M), Table S2 (MIF-covalent inhibitor complexes),
Table S3 (P1M, M2A and DP1), and Table S4 (Q24A/Q25A, Y36A, K66A and
N109A).ACCESSION NUMBERS
Coordinates and structural factors have been deposited in the PDB under the
accession codes PDB: 4GRN (PA2M), 4GRO (PA3M), 4P01 (MIF-1), 4TRF (MIF-
10), 4P0H (MIF-14), 4PLU (MIF-21), 4PKZ (P1M), 4XX7 (M2A), 4XX8 (DP1),
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